Literature DB >> 24081407

Screening for metabolic risk among patients with severe mental illness and diabetes: a national comparison.

Alex J Mitchell, Sheila Ann Hardy.   

Abstract

OBJECTIVE: People with severe mental illness have a higher risk of developing cardiovascular disease and die sooner than the general population. This study of a national sample of primary care patients in the United Kingdom compared screening for cardiometabolic risk factors among patients with severe mental illness and diabetes.
METHODS: Screening for cardiovascular disease among 2,488,948 patients with diabetes (2010-2011) and 422,966 patients with severe mental illness (2011-2012) at 8,123 primary care practices was compared.
RESULTS: The percentage of patients who received screening across four parameters (body mass index, blood pressure, blood glucose, and cholesterol) in the previous 15 months was higher among patients with diabetes than among those with severe mental illness (97.3% versus 74.7%, p<.001).
CONCLUSIONS: The proportion of patients in primary care who were given screening for cardiometabolic risk was much lower among those with severe mental illness than among those with diabetes.

Entities:  

Mesh:

Year:  2013        PMID: 24081407     DOI: 10.1176/appi.ps.201200514

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  10 in total

1.  Physical health indicators in SMI.

Authors:  Julie Langan-Martin; Daniel Smith; Stewart Mercer
Journal:  Br J Gen Pract       Date:  2015-01       Impact factor: 5.386

2.  Cardiovascular preventive care for patients with serious mental illness.

Authors:  Sarah Ritchie; Laura Muldoon
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

Review 3.  Diabetes mellitus and severe mental illness: mechanisms and clinical implications.

Authors:  Richard I G Holt; Alex J Mitchell
Journal:  Nat Rev Endocrinol       Date:  2014-12-02       Impact factor: 43.330

Review 4.  The co-occurrence of mental disorders in children and adolescents with intellectual disability/intellectual developmental disorder.

Authors:  Kerim M Munir
Journal:  Curr Opin Psychiatry       Date:  2016-03       Impact factor: 4.741

5.  Glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study.

Authors:  Pauline Mj Steylen; Frank Mma van der Heijden; Witte Jg Hoogendijk; Willem Ma Verhoeven
Journal:  Diabetes Metab Syndr Obes       Date:  2015-01-23       Impact factor: 3.168

6.  Status of primary and secondary mental healthcare of people with severe mental illness: an epidemiological study from the UK PARTNERS2 programme.

Authors:  Siobhan Reilly; Catherine McCabe; Natalie Marchevsky; Maria Green; Linda Davies; Natalie Ives; Humera Plappert; Jon Allard; Tim Rawcliffe; John Gibson; Michael Clark; Vanessa Pinfold; Linda Gask; Peter Huxley; Richard Byng; Max Birchwood
Journal:  BJPsych Open       Date:  2021-02-15

Review 7.  Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity.

Authors:  J Assies; R J T Mocking; A Lok; H G Ruhé; F Pouwer; A H Schene
Journal:  Acta Psychiatr Scand       Date:  2014-03-21       Impact factor: 6.392

8.  Cardiovascular disease treatment among patients with severe mental illness: a data linkage study between primary and secondary care.

Authors:  Charlotte Woodhead; Mark Ashworth; Matthew Broadbent; Felicity Callard; Matthew Hotopf; Peter Schofield; Murat Soncul; Robert J Stewart; Max J Henderson
Journal:  Br J Gen Pract       Date:  2016-04-25       Impact factor: 5.386

Review 9.  Big data for bipolar disorder.

Authors:  Scott Monteith; Tasha Glenn; John Geddes; Peter C Whybrow; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2016-04-11

10.  Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides.

Authors:  Yanmei Li; Ruibing Su; Shuqin Xu; Qingjun Huang; Haiyun Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-27       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.